{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:34Z","timestamp":1792831054336,"version":"4.5.0"},"reference-count":192,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304280"],"award-info":[{"award-number":["82304280"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2682026CX212"],"award-info":[{"award-number":["2682026CX212"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110640","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:57:21Z","timestamp":1791874641000},"page":"110640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of EZH2-based combination therapies and dual-target inhibitors for antitumor effects"],"prefix":"10.1016","volume":"183","author":[{"given":"Yiming","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110640_bb0005","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110640_bb0010","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1007\/s11427-022-2240-6","article-title":"Overview and countermeasures of cancer burden in China","volume":"66","author":"Wang","year":"2023","journal-title":"Sci. China. Life Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semcancer.2021.03.025","article-title":"Cancer epigenetics: past, present and future","volume":"83","author":"Lee","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0020","doi-asserted-by":"crossref","DOI":"10.48130\/epi-0025-0003","article-title":"Statistical analysis of DNA methylation patterns of tumor suppressor genes in breast cancer","volume":"18","author":"Sun","year":"2025","journal-title":"Epigenet. Insights"},{"key":"10.1016\/j.bioorg.2026.110640_bb0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41422-021-00606-6","article-title":"Mechanisms of Polycomb group protein function in cancer","volume":"32","author":"Parreno","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0035","doi-asserted-by":"crossref","DOI":"10.48130\/epi-0025-0014","article-title":"DNA methylation and histone modifications: conserved, divergent, and synergistic epigenetic regulation across plants and animals","volume":"18","author":"Liu","year":"2025","journal-title":"Epigenet. Insights"},{"key":"10.1016\/j.bioorg.2026.110640_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0045","article-title":"NF-\u03baB-mediated enhancement of H3K27me3 through EZH2: a mechanism to suppress pyocyanin-induced autophagy in macrophages","volume":"30","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-024-02105-0","article-title":"EZH2-STAT3 signaling pathway regulates GSDMD-mediated pyroptosis in glioblastoma","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bioorg.2026.110640_bb0055","article-title":"Downregulation of EZH2 promotes renal epithelial cellular senescence and kidney aging","volume":"39","author":"Zhang","year":"2025","journal-title":"FASEB J."},{"key":"10.1016\/j.bioorg.2026.110640_bb0060","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.7150\/jca.43446","article-title":"LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K\/AKT pathway","volume":"11","author":"Dai","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0065","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1038\/s41388-020-01484-9","article-title":"EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis","volume":"39","author":"Guan","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110640_bb0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2020.09.003","article-title":"Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung Cancer","volume":"495","author":"Quan","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110640_bb0075","doi-asserted-by":"crossref","DOI":"10.48130\/targetome-0025-0002","article-title":"Targetome-guided combination drug discovery as next-generation therapeutics","volume":"1","author":"Liu","year":"2025","journal-title":"Targetome"},{"key":"10.1016\/j.bioorg.2026.110640_bb0080","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/sj.ejhg.5200439","article-title":"The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders","volume":"8","author":"Cardoso","year":"2000","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.bioorg.2026.110640_bb0085","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2026.110640_bb0090","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ajpath.2021.01.013","article-title":"Noncanonical functions of the Polycomb group protein EZH2 in breast Cancer","volume":"191","author":"Anwar","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0095","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41556-021-00744-4","article-title":"EZH2 accompanies prostate Cancer progression","volume":"23","author":"Xin","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","article-title":"Histone methyltransferase EZH2: a therapeutic target for ovarian Cancer","volume":"17","author":"Jones","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110640_bb0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/OTT.S42453","article-title":"Update of research on the role of EZH2 in cancer progression","volume":"6","author":"Shen","year":"2013","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.bioorg.2026.110640_bb0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fgene.2021.658241","article-title":"Comprehensive analysis of the expression characteristics of the enhancer of the Zeste homolog 2 gene in Pan-Cancer","volume":"12","author":"Kang","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.bioorg.2026.110640_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020425","article-title":"EZH2: an accomplice of gastric cancer","volume":"15","author":"Yu","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110640_bb0120","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/cas.14840","article-title":"The noncanonical role of EZH2 in cancer","volume":"112","author":"Huang","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216706","article-title":"EZH2-mediated development of therapeutic resistance in cancer","volume":"586","author":"Kaur","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110640_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115461","article-title":"Recent advances in EZH2-based dual inhibitors in the treatment of cancers","volume":"256","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-021-01045-1","article-title":"Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors","volume":"13","author":"Li","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bioorg.2026.110640_bb0140","article-title":"Safety profile of EZH2 inhibitors for cancer: a systematic review and meta-analysis","volume":"13","author":"Zhao","year":"2025","journal-title":"PeerJ"},{"key":"10.1016\/j.bioorg.2026.110640_bb0145","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1038\/s41467-018-06656-6","article-title":"SWI\/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells","volume":"9","author":"Wu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110640_bb0150","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","article-title":"Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas","volume":"131","author":"Bisserier","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110640_bb0155","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(24)02319-5","article-title":"Radiotherapy toxicities: mechanisms, management, and future directions","volume":"405","author":"Verginadis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110640_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-024-00239-2","article-title":"Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer","volume":"6","author":"Gu","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.bioorg.2026.110640_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010183","article-title":"Overcoming chemotherapy resistance in metastatic cancer: a comprehensive review","volume":"12","author":"Eslami","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2026.110640_bb0175","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01801-2","article-title":"Molecular mechanisms of tumor resistance to radiotherapy","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0190","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1007\/s13277-015-4416-9","article-title":"Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating dicer expression","volume":"37","author":"Cai","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0205","first-page":"4249","article-title":"Pharmacological inhibition of EZH2 combined with DNA-damaging agents interferes with the DNA damage response in MM cells","volume":"19","author":"Xu","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2026.110640_bb0210","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41388-018-0459-x","article-title":"RETRACTED ARTICLE: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer","volume":"38","author":"Sun","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110640_bb0215","article-title":"MiR-138 acts as a tumor suppressor by targeting EZH2 and enhances cisplatin-induced apoptosis in osteosarcoma cells","volume":"11","author":"Ahmad","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.110640_bb0220","first-page":"1874","article-title":"Enhancing chemotherapy sensitivity by targeting PcG via the ATM\/p53 pathway","volume":"7","author":"Gao","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0225","doi-asserted-by":"crossref","first-page":"911","DOI":"10.7150\/ijbs.64752","article-title":"SOX8 affects Tumoral SPARC expression by regulating EZH2 to attenuate effectiveness of albumin-bound paclitaxel in PDAC","volume":"18","author":"Yuan","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0230","first-page":"6662","article-title":"Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma","volume":"7","author":"Fan","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0180","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature14122","article-title":"EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors","volume":"520","author":"Fillmore","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110640_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110773","article-title":"Interplay between EZH2\/\u03b2-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets","volume":"109","author":"Milan","year":"2023","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bioorg.2026.110640_bb0240","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.7150\/thno.34700","article-title":"Overcoming EZH2 inhibitor resistance by Taxane in PTEN-mutated Cancer","volume":"9","author":"Ma","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.110640_bb0245","doi-asserted-by":"crossref","first-page":"649","DOI":"10.5534\/wjmh.220073","article-title":"Docetaxel enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate Cancer cells via epigenetic gene regulation by enhancer of Zeste homolog 2","volume":"41","author":"Lee","year":"2023","journal-title":"The World Journal of Men's Health."},{"key":"10.1016\/j.bioorg.2026.110640_bb0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12885-018-5228-2","article-title":"Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells","volume":"19","author":"Qiu","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0250","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1535-7163.MCT-12-0037","article-title":"Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin a with gemcitabine in pancreatic Cancer cells","volume":"11","author":"Avan","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110640_bb0185","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1158\/1078-0432.CCR-18-4024","article-title":"EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy","volume":"25","author":"Puppe","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155271","article-title":"Exosome miR-101-3p derived from bone marrow mesenchymal stem cells promotes radiotherapy sensitivity in non-small cell lung cancer by regulating DNA damage repair and autophagy levels through EZH2","volume":"256","author":"Sun","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bioorg.2026.110640_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101316","article-title":"EZH2 targeting to improve the sensitivity of acquired radio-resistance bladder cancer cells","volume":"16","author":"Zhang","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0265","first-page":"45","article-title":"EZH2 downregulation augments the effect of irradiation in reducing pancreatic Cancer cell proliferation in vitro","volume":"50","author":"Agrawal","year":"2020","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0270","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1111\/jcmm.17135","article-title":"miR-126-5p enhances radiosensitivity of lung adenocarcinoma cells by inhibiting EZH2 via the KLF2\/BIRC axis","volume":"26","author":"Han","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110640_bb0200","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/neuonc\/nos285","article-title":"Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells","volume":"15","author":"Alimova","year":"2013","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0275","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110640_bb0280","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110640_bb0285","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110640_bb0290","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0600","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2023-186614","article-title":"EZH2 inhibition overcomes immunomodulatory drug (IMiD) resistance in multiple myeloma cell lines in a Cereblon pathway dependent manner","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110640_bb0605","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1172\/JCI99760","article-title":"Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy","volume":"128","author":"Goswami","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2026.110640_bb0610","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1878-0261.12157","article-title":"Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner","volume":"12","author":"Dimopoulos","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110243","article-title":"Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC","volume":"119","author":"Liu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0620","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128474","article-title":"Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism","volume":"4","author":"Hamaidia","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.bioorg.2026.110640_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110918","article-title":"Attenuated salmonella-delivered PD-1 siRNA enhances the antitumor effects of EZH2 inhibitors in colorectal cancer","volume":"124","author":"Lv","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0630","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-19-1351","article-title":"Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck Cancer","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0635","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1007\/s12672-025-03753-z","article-title":"S-adenosylmethionine enhances anti-PD-1 efficacy in uveal melanoma by targeting EZH2","volume":"16","author":"Gao","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0640","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1578665","article-title":"Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway","volume":"16","author":"Jeong","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0645","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.7150\/jca.73291","article-title":"EZH2 inhibition activates dsRNA-interferon axis stress and promotes response to PD-1 checkpoint blockade in NSCLC","volume":"13","author":"Qiu","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0595","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s40425-019-0784-9","article-title":"EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma","volume":"7","author":"Xiao","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0590","article-title":"EZH2 inhibition enhances PD-L1 protein stability through USP22-mediated deubiquitination in colorectal cancer","volume":"11","author":"Huang","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0650","article-title":"Study on the effect of EZH2 inhibitor combined with TIGIT monoclonal antibody against multiple myeloma cells","volume":"24","author":"Liu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0655","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092541","article-title":"Combination treatment with GSK126 and Pomalidomide induces B-cell differentiation in EZH2 gain-of-function mutant diffuse large B-cell lymphoma","volume":"12","author":"Park","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110640_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011650","article-title":"EZH2 inhibition and 5-azacytidine enhance antitumor immunity in PTEN-deficient glioblastoma by activation viral mimicry response","volume":"13","author":"Zhu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0340","doi-asserted-by":"crossref","DOI":"10.1186\/1868-7083-6-19","article-title":"Epigenetic therapy of acute myeloid leukemia using 5-aza-2\u2032-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation","volume":"6","author":"Momparler","year":"2014","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bioorg.2026.110640_bb0345","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1111\/cas.14207","article-title":"Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma","volume":"110","author":"Rizk","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0305","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","article-title":"AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution","volume":"635","author":"Schade","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110640_bb0350","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3892\/ijo.2021.5177","article-title":"APR-246 combined with 3-deazaneplanocin a, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells","volume":"58","author":"de la Rosa","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216445","article-title":"Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer","volume":"578","author":"Chen","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110640_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115200","article-title":"Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer","volume":"404","author":"Shankar","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0365","doi-asserted-by":"crossref","first-page":"9911","DOI":"10.1074\/jbc.RA119.008152","article-title":"Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer","volume":"294","author":"Bai","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0330","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","article-title":"An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer","volume":"23","author":"Davies","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0370","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/epi-2023-0374","article-title":"Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response","volume":"16","author":"Fischetti","year":"2024","journal-title":"Epigenomics"},{"key":"10.1016\/j.bioorg.2026.110640_bb0375","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13058-022-01534-y","article-title":"Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer","volume":"24","author":"Ratz","year":"2022","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0380","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/s41416-024-02661-3","article-title":"Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma","volume":"130","author":"Landman","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0385","doi-asserted-by":"crossref","first-page":"216226","DOI":"10.1016\/j.canlet.2023.216226","article-title":"Combined inhibition of EZH2 and the autotaxin-LPA-LPA2 axis exerts synergistic antitumor effects on colon cancer cells","volume":"566","author":"Long","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110640_bb0390","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1182\/bloodadvances.2020002580","article-title":"Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes","volume":"4","author":"Scholze","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bioorg.2026.110640_bb0395","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2022.2163242","article-title":"Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells","volume":"38","author":"Negri","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0400","article-title":"Remarkable synergy when combining EZH2 inhibitors with YM155 is H3K27me3-independent","volume":"15","author":"Yang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110640_bb0310","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/nm.4415","article-title":"Targeting glioma stem cells through combined BMI1 and EZH2 inhibition","volume":"23","author":"Jin","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110640_bb0405","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12032-023-02147-x","article-title":"EZH2 inhibitor Tazemetostat synergizes with JQ-1 in esophageal cancer by inhibiting c-Myc signaling pathway","volume":"40","author":"Ding","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0315","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ads6385","article-title":"BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling","volume":"11","author":"Yin","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2026.110640_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104752","article-title":"Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth","volume":"25","author":"Chava","year":"2022","journal-title":"Iscience"},{"key":"10.1016\/j.bioorg.2026.110640_bb0415","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41698-024-00653-3","article-title":"Combined inhibition of EZH2 and CDK4\/6 perturbs endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma","volume":"8","author":"Freitag","year":"2024","journal-title":"Npj Precision Oncology."},{"key":"10.1016\/j.bioorg.2026.110640_bb0420","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3324\/haematol.2019.222935","article-title":"EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma","volume":"105","author":"Xie","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2026.110640_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215899","article-title":"DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma","volume":"548","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110640_bb0430","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2022.215899","article-title":"DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma","volume":"548","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110640_bb0435","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1038\/s41418-021-00824-w","article-title":"TCF3 is epigenetically silenced by EZH2 and DNMT3B and functions as a tumor suppressor in endometrial cancer","volume":"28","author":"Gui","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioorg.2026.110640_bb0440","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.2024025500","article-title":"Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma","volume":"145","author":"G\u00f6bel","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110640_bb0445","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10120-020-01097-x","article-title":"Inhibition of EZH2 and activation of ERR\u03b3 synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway","volume":"24","author":"Huang","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0450","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13046-023-02659-4","article-title":"FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling","volume":"42","author":"Yang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0455","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41375-023-02131-4","article-title":"FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia","volume":"38","author":"Sung","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110640_bb0460","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12032-022-01683-2","article-title":"Unique combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growth","volume":"39","author":"Alexanian","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0465","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10637-023-01370-7","article-title":"Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth","volume":"41","author":"Alexanian","year":"2023","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bioorg.2026.110640_bb0470","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40364-025-00800-3","article-title":"A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor","volume":"13","author":"Shan","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0475","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1158\/1535-7163.MCT-18-0348","article-title":"Histone deacetylase inhibitors synergize with catalytic inhibitors of EZH2 to exhibit antitumor activity in small cell carcinoma of the ovary, hypercalcemic type","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110640_bb0480","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-18-3989","article-title":"Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas","volume":"25","author":"Lue","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0485","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41419-025-07775-x","article-title":"EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma","volume":"16","author":"Wu","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110640_bb0490","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70626","article-title":"Dual targeting EZH2 and histone deacetylases in human uterine sarcoma cells under both 2D and 3D culture conditions","volume":"29","author":"Omran","year":"2025","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110640_bb0495","doi-asserted-by":"crossref","DOI":"10.3390\/cells13030219","article-title":"EZH2 inhibition sensitizes IDH1R132H-mutant gliomas to histone deacetylase inhibitor","volume":"13","author":"Sprinzen","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110640_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002038","article-title":"Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC","volume":"21","author":"Schade","year":"2023","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0505","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/cancers13174249","article-title":"The synergistic anti-tumor activity of EZH2 inhibitor SHR2554 and HDAC inhibitor Chidamide through ORC1 reduction of DNA replication process in diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110640_bb0510","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/cas.12957","article-title":"Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells","volume":"107","author":"Takashina","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24031963","article-title":"Resistance to BRAF inhibitors: EZH2 and its downstream targets as potential therapeutic options in melanoma","volume":"24","author":"Uebel","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0520","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2017.10.015","article-title":"Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo","volume":"413","author":"Wen","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110640_bb0525","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1111\/jcmm.15007","article-title":"Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring by synergistically decreasing global trimethylation of H3K27","volume":"24","author":"Fu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110640_bb0530","first-page":"346","article-title":"Targeting MAT2A synergistically induces DNA damage in osteosarcoma cells through EZH2-mediated H3K27me3 modification","volume":"55","author":"Yang","year":"2025","journal-title":"J. Orthop. Transl."},{"key":"10.1016\/j.bioorg.2026.110640_bb0535","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccell.2019.12.015","article-title":"EZH2 inhibition sensitizes CARM1-high, homologous recombination proficient ovarian cancers to PARP inhibition","volume":"37","author":"Karakashev","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110640_bb0540","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl2804","article-title":"EZH2 directly methylates PARP1 and regulates its activity in cancer","volume":"10","author":"Meng","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2026.110640_bb0545","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2021.10.010","article-title":"EZH2 inhibition confers-driven lung tumors enhanced sensitivity to PI3K inhibition","volume":"524","author":"Chen","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110640_bb0550","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.835","article-title":"Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3K\u03b1 inhibitors in oesophageal squamous cell carcinoma","volume":"12","author":"Xing","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.110640_bb0555","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.7150\/thno.53023","article-title":"PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression","volume":"11","author":"Yang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.110640_bb0560","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-025-02734-0","article-title":"EZH2 inhibitor and Vismodegib synergistically inhibit the growth and metastasis of medulloblastoma","volume":"42","author":"Xu","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0565","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jid.2021.08.437","article-title":"EZH2 inhibitor enhances the STING agonist.Induced antitumor immunity in melanoma","volume":"142","author":"Xu","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0570","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/jcp.26107","article-title":"12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: a novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells","volume":"233","author":"Marchesi","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0295","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0300","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrm2822","article-title":"The nuts and bolts of AGC protein kinases","volume":"11","author":"Pearce","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0320","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.cell.2013.02.014","article-title":"Transcriptional regulation and its misregulation in disease","volume":"152","author":"Lee","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110640_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082296","article-title":"Transcription factors in cancer development and therapy","volume":"12","author":"Vishnoi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110640_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0580","article-title":"A new trend in cancer treatment: the combination of epigenetics and immunotherapy","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0585","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0660","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET proteins as targets for anticancer treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110640_bb0665","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0670","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s41594-019-0309-8","article-title":"Bromodomain biology and drug discovery","volume":"26","author":"Zaware","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0675","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0680","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","article-title":"Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors","volume":"175","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110640_bb0685","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1021\/acs.jmedchem.1c01876","article-title":"Design and synthesis of dual EZH2\/BRD4 inhibitors to target solid tumors","volume":"65","author":"Guo","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117386","article-title":"Design, synthesis and mechanism studies of dual EZH2\/BRD4 inhibitors for cancer therapy","volume":"91","author":"Chen","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0695","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1021\/acs.jmedchem.2c01607","article-title":"Design, synthesis, and biological evaluation of a potent dual EZH2-BRD4 inhibitor for the treatment of some solid tumors","volume":"66","author":"Huang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0700","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1021\/acs.jmedchem.0c00744","article-title":"Recent developments in the biology and medicinal chemistry of CDK9 inhibitors: an update","volume":"63","author":"Wu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123039","article-title":"Targeting CDK9 for the treatment of glioblastoma","volume":"13","author":"Ranjan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110640_bb0710","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/s41401-021-00796-0","article-title":"Targeting cyclin-dependent kinase 9 in cancer therapy","volume":"43","author":"Shen","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2026.110640_bb0715","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1039\/D2MD00040G","article-title":"CDK9 inhibitors in cancer research","volume":"13","author":"Huang","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117773","article-title":"Design and synthesis of CDK9\/EZH2 dual-target inhibitors to achieve synergistic antitumor effects","volume":"294","author":"Tian","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2026.130747","article-title":"Design and synthesis of dual-target CDK9-EZH2 inhibitors using a pharmacophore fusion strategy","volume":"141","author":"Han","year":"2026","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110640_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173827","article-title":"Targeting EHMT2\/G9a for cancer therapy: Progress and perspective","volume":"893","author":"Jan","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0735","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/acs.jmedchem.4c02781","article-title":"Current and emerging approaches targeting G9a for the treatment of various diseases","volume":"68","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0740","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16122175","article-title":"G9a in cancer: mechanisms, therapeutic advancements, and clinical implications","volume":"16","author":"Ni","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110640_bb0745","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ejmech.2019.06.072","article-title":"Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents","volume":"179","author":"Cao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0750","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0959-8049(14)70680-X","article-title":"Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells","volume":"50","author":"Brown","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0755","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/1535-7163.MCT-21-0743","article-title":"Dual G9A\/EZH2 inhibition stimulates antitumor immune response in ovarian high-grade serous carcinoma","volume":"21","author":"Spiliopoulou","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110640_bb0760","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1076458","article-title":"Dual inhibition of EZH2 and G9A\/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells","volume":"11","author":"Sbirkov","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0765","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1021\/acs.jmedchem.3c00003","article-title":"Discovery of dual lysine methyltransferase G9a and EZH2 inhibitors with in vivo efficacy against malignant rhabdoid tumor","volume":"66","author":"Shi","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0770","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","article-title":"Histone deacetylases and cancer","volume":"6","author":"Barneda-Zahonero","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0775","article-title":"Mechanisms of HDACs in cancer development","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0780","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.110640_bb0785","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1158\/1535-7163.MCT-18-0348","article-title":"Histone deacetylase inhibitors synergize with catalytic inhibitors of EZH2 to exhibit antitumor activity in small cell carcinoma of the ovary, hypercalcemic type","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110640_bb0790","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-18-3989","article-title":"Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas","volume":"25","author":"Lue","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0795","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/acsmedchemlett.0c00014","article-title":"Design of First-in-Class Dual EZH2\/HDAC inhibitor: biochemical activity and biological evaluation in Cancer cells","volume":"11","author":"Romanelli","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110640_bb0800","doi-asserted-by":"crossref","first-page":"12838","DOI":"10.1021\/acs.jmedchem.2c00673","article-title":"Histone deacetylase and enhancer of Zeste homologue 2 dual inhibitors presenting a synergistic effect for the treatment of hematological malignancies","volume":"65","author":"Lu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107964","article-title":"Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies","volume":"153","author":"Zhang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.119006","article-title":"Design, synthesis and biological evaluation of EZH2\/HDAC dual inhibitors for the treatment of lymphomas","volume":"316","author":"Sun","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0815","doi-asserted-by":"crossref","first-page":"46752","DOI":"10.1039\/D6RA04928A","article-title":"Design, synthesis and antiproliferative activity of pyridone derivatives as potent enhancer of zeste homologue 2\/histone deacetylase dual inhibitors","volume":"16","author":"Tan","year":"2026","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110640_bb0820","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/onc.2012.510","article-title":"The growing complexity of HIF-1\u03b1's role in tumorigenesis: DNA repair and beyond","volume":"32","author":"Rohwer","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110640_bb0825","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.110640_bb0830","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"The interplay between HIF-1\u03b1 and EZH2 in lung cancer and dual-targeted drug therapy","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bioorg.2026.110640_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107419","article-title":"2,2- dimethylbenzopyran derivatives containing pyridone structural fragments as selective dual-targeting inhibitors of HIF-1\u03b1 and EZH2 for the treatment of lung cancer","volume":"147","author":"Xu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0840","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010060","article-title":"Heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy","volume":"9","author":"Yun","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110640_bb0845","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.3390\/ijms221910317","article-title":"Role of HSP90 in cancer","volume":"22","author":"Birbo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110640_bb0850","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bcp.2019.04.010","article-title":"Targeting hsp90 family members: a strategy to improve cancer cell death","volume":"164","author":"Calderon","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0855","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.acr.2021.03.006","article-title":"Targeting heat shock protein 90 for anti-cancer drug development","volume":"152","author":"Aswad","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0860","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/1078-0432.CCR-13-2571","article-title":"Stressing the development of small molecules targeting HSP90","volume":"20","author":"Neckers","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0865","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/acs.jmedchem.9b00940","article-title":"Heat shock protein 90 inhibitors: An update on achievements, challenges, and future directions","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0870","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1021\/acs.jmedchem.3c02053","article-title":"First-in-class dual EZH2-HSP90 inhibitor eliciting striking Antiglioblastoma activity in vitro and in vivo","volume":"67","author":"Sharma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0875","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110640_bb0880","article-title":"Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105958","article-title":"Therapeutic potential of targeting LSD1\/KDM1A in cancers","volume":"175","author":"Zhang","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0890","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/acs.jmedchem.3c02133","article-title":"Combination therapy and dual-target inhibitors based on LSD1: new emerging tools in Cancer therapy","volume":"67","author":"Shen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117651","article-title":"Research progress of LSD1-based dual-target agents for cancer therapy","volume":"101","author":"Yang","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0900","doi-asserted-by":"crossref","first-page":"15586","DOI":"10.1021\/acs.jmedchem.4c01250","article-title":"Design, synthesis, and biological evaluation of potent EZH2\/LSD1 dual inhibitors for prostate cancer","volume":"67","author":"Le","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0905","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc3748","article-title":"New PARP targets for cancer therapy","volume":"14","author":"Vyas","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110640_bb0910","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/med.21442","article-title":"Therapeutic targeting of poly(ADP-ribose) Polymerase-1 (PARP1) in Cancer: current developments, therapeutic strategies, and future opportunities","volume":"37","author":"Rajawat","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110640_bb0915","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/acs.jmedchem.4c02642","article-title":"The potential of PARP inhibitors as antitumor drugs and the perspective of molecular design","volume":"68","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0920","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0925","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-12-0163","article-title":"Molecular pathways: targeting PARP in Cancer treatment","volume":"19","author":"Do","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110640_bb0930","doi-asserted-by":"crossref","first-page":"12630","DOI":"10.1021\/acs.jmedchem.1c00567","article-title":"Discovery of first-in-class dual PARP and EZH2 inhibitors for triple-negative breast Cancer with wild-type BRCA","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116054","article-title":"Dual target PARP1\/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy","volume":"265","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118287","article-title":"Discovery of selective PARP1\/EZH2 inhibitor inducing PANoptosis in triple-negative breast cancer","volume":"302","author":"Fan","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110640_bb0945","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.110640_bb0950","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.bioorg.2026.110640_bb0955","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110640_bb0960","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1886069","article-title":"Rational design and biological validation of EZH2\/PD-L1 bifunctional inhibitors for colorectal cancer immunotherapy","volume":"17","author":"Guan","year":"2026","journal-title":"Front. Immunol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:04:15Z","timestamp":1792829055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826011764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":192,"alternative-id":["S0045206826011764"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110640","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of EZH2-based combination therapies and dual-target inhibitors for antitumor effects","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110640"}}